These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 37576702)
1. Efficacy and dose response of Martoni CJ; Srivastava S; Damholt A; Leyer GJ World J Gastroenterol; 2023 Jul; 29(28):4451-4465. PubMed ID: 37576702 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial. Anderle K; Wolzt M; Moser G; Keip B; Peter J; Meisslitzer C; Gouya G; Freissmuth M; Tschegg C World J Gastroenterol; 2022 Dec; 28(46):6573-6588. PubMed ID: 36569277 [TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Srivastava S; Basak U; Naghibi M; Vijayakumar V; Parihar R; Patel J; Jadon PS; Pandit A; Dargad RR; Khanna S; Kumar S; Day R Gut Microbes; 2024; 16(1):2338322. PubMed ID: 38630015 [TBL] [Abstract][Full Text] [Related]
5. Effect of Oral Intake of Jung K; Kim A; Lee JH; Cho D; Seo J; Jung ES; Kang HJ; Roh J; Kim W Nutrients; 2022 May; 14(10):. PubMed ID: 35631156 [TBL] [Abstract][Full Text] [Related]
6. Palmitoylethanolamide and polydatin in pediatric irritable bowel syndrome: A multicentric randomized controlled trial. Di Nardo G; Bernardo L; Cremon C; Barbara G; Felici E; Evangelisti M; Ferretti A; Furio S; Piccirillo M; Coluzzi F; Parisi P; Mauro A; Di Mari C; D'Angelo F; Mennini M Nutrition; 2024 Jun; 122():112397. PubMed ID: 38479039 [TBL] [Abstract][Full Text] [Related]
7. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. Ishaque SM; Khosruzzaman SM; Ahmed DS; Sah MP BMC Gastroenterol; 2018 May; 18(1):71. PubMed ID: 29801486 [TBL] [Abstract][Full Text] [Related]
8. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. Lyra A; Hillilä M; Huttunen T; Männikkö S; Taalikka M; Tennilä J; Tarpila A; Lahtinen S; Ouwehand AC; Veijola L World J Gastroenterol; 2016 Dec; 22(48):10631-10642. PubMed ID: 28082816 [TBL] [Abstract][Full Text] [Related]
9. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points. Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331 [TBL] [Abstract][Full Text] [Related]
10. Different therapies of Chinese herbal medicine for diarrhea-predominant irritable bowel syndrome: A network meta-analysis of double-blinded, placebo-controlled trials. Liu N; Li J; Wang Y; Zhang S J Ethnopharmacol; 2023 Dec; 317():116672. PubMed ID: 37328079 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578 [TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Stevenson C; Blaauw R; Fredericks E; Visser J; Roux S Nutrition; 2014 Oct; 30(10):1151-7. PubMed ID: 25194614 [TBL] [Abstract][Full Text] [Related]
13. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Kemppinen A; Howell C; Allgar V; Dodd M; Gregson J; Knowles C; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y Trials; 2020 Jan; 21(1):122. PubMed ID: 32000822 [TBL] [Abstract][Full Text] [Related]
15. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790 [TBL] [Abstract][Full Text] [Related]
16. The Effectiveness of Synbiotic Preparation Containing Skrzydło-Radomańska B; Prozorow-Król B; Cichoż-Lach H; Majsiak E; Bierła JB; Kosikowski W; Szczerbiński M; Gantzel J; Cukrowska B Nutrients; 2020 Jul; 12(7):. PubMed ID: 32635661 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial. Lacy BE; King J; Shortino D; Schaumburg C; Haag-Molkenteller C; Chey WD Neurogastroenterol Motil; 2022 Dec; 34(12):e14448. PubMed ID: 35975404 [TBL] [Abstract][Full Text] [Related]
18. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922 [TBL] [Abstract][Full Text] [Related]
19. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Skrzydło-Radomańska B; Prozorow-Król B; Cichoż-Lach H; Majsiak E; Bierła JB; Kanarek E; Sowińska A; Cukrowska B Nutrients; 2021 Feb; 13(3):. PubMed ID: 33652763 [TBL] [Abstract][Full Text] [Related]
20. Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome. Nee J; Salley K; Ludwig AG; Sommers T; Ballou S; Takazawa E; Duehren S; Singh P; Iturrino J; Katon J; Lee HN; Rangan V; Lembo AJ Clin Transl Gastroenterol; 2019 Dec; 10(12):e00110. PubMed ID: 31800542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]